author-photo

Chan C. Whiting

Stanford University

22

Papers

738

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

A randomized Phase 2b study of GVAX pancreas and CRS-207 compared to chemotherapy in previously-treated metastatic pancreatic adenocarcinoma patients (ECLIPSE Study)

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (75)
Abstract 3606: Blockade of the PPARα metabolic checkpoint with TPST-1120 suppresses tumor growth and stimulates anti-tumor immunity

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Phase 1/1b multicenter trial of TPST-1120, a peroxisome proliferator-activated receptor alpha (PPARα) antagonist as a single agent (SA) or in combination in patients with advanced solid tumors.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (31)
Clinical and immune characteristics of rapid dropout and long-term survival in a phase II safety and efficacy study of combination CRS-207/GVAX immunotherapy in pancreatic cancer.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy

2015 Arthritis Research & Therapy
Show All
- Source
- Cite
- Save
Citations (42)
Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging

2015 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (68)
Inflammation and Hyperglycemia Mediate Deaf1 Splicing in the Pancreatic Lymph Nodes via Distinct Pathways During Type 1 Diabetes

2015 Diabetes
Show All
- Source
- Cite
- Save
Citations (17)
Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: Clinical update on long term survival and biomarker correlates to overall survival.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness.

2011 FEBS Journal
Show All
- Source
- Cite
- Save
Citations (39)